ReviewFrontiers in immunology2026
N-Myc and STAT interactor as a context-dependent switch in innate antiviral immunity.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enrichment of the TRIM21-IgG complex in placental villi during HIV-1 infection.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N-Myc and STAT interactor (NMI), initially identified as a Myc- and STAT-associated protein, is increasingly recognized as a regulatory node in innate antiviral immunity. Current evidence indicates that NMI does not exert a fixed antiviral or proviral effect. Instead, its functional output is shaped by interacting partners, signaling pathway context, subcellular localization, and stage of infection. In selected acute RNA virus models, NMI suppresses IRF7-dependent type I interferon (IFN-I) signaling. In the IAV model, this involves an NMI-IFP35 complex coupled to the TRIM21-IRF7 axis that promotes IRF7 degradation, suppresses IFN-I responses, and thereby facilitates viral replication. In foamy virus infection, by contrast, NMI directly binds the viral transactivator Tas, retains it in the cytoplasm, and suppresses viral transcription, thus acting as a host restriction factor. In human cytomegalovirus (HCMV) infection, NMI appears to function as a host pathway component targeted by viral antagonism, as the viral protein UL23 interferes with the NMI-STAT1/IFN-γ axis and dampens antiviral gene expression. In addition, extracellular NMI and IFP35 can function as damage-associated molecular patterns that amplify inflammation. Together, these findings support the view that NMI acts as a context-dependent molecular switch rather than a unidirectional effector in innate antiviral immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.